SAStephen Amankwah

Stephen Amankwah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephen Amankwah has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Tesfaye Kassa

    School of Medical Laboratory Sciences, Institute of Health, Jimma University, Jimma, Ethiopia

    3 shared publications
  • Bradford D. Gessner

    Vaccines Medical Development, Scientific and Clinical Affairs Pfizer Inc Collegeville Pennsylvania USA

    2 shared publications
  • Elizabeth Begier

    Global Medical Development Scientific and Clinical Affairs Pfizer Vaccines Dublin Ireland

    2 shared publications
  • Emil Stefańczyk

    Plant Breeding and Acclimatization Institute-National Research Institute, Młochów Research Centre, Młochów, Poland

    2 shared publications
  • Franklin Nyanzu

    Department of Epidemiology and Disease Control, School of Public Health University of Ghana Accra Ghana

    2 shared publications
  • Harish Nair

    Centre for Global Health, Usher Institute University of Edinburgh Edinburgh UK

    2 shared publications

Latest Publications

  • Molecular insights into the long terminal repeat regions of therapeutic staphylococcal Twortvirinae phages

    by Stephen Amankwah, Laura Wicke, Łukasz Kałuski, Emil Stefańczyk, Małgorzata Łobocka

  • Open Access

    A versatile toolset for Staphylococcus aureus gene inactivation enables testing of anti-phage defense systems in native genetic backgrounds

    by Łukasz Kałuski, Stephen Amankwah, Laura Wicke, Ján Bíňovský, Emil Stefańczyk, Ivana Mašlaňová, Lucie Kuntová, Roman Pantůček, Małgorzata Łobocka

    Functional gene analysis of Staphylococcus aureus across different strains requires the development of genetic engineering tools. In studies on phage thera

  • Open Access

    Burden of Respiratory Syncytial Virus (RSV) Infection Among Adults in Nursing and Care Homes: A Systematic Review

    by Richard Osei‐Yeboah, Stephen Amankwah, Elizabeth Begier, Miranda Adedze, Franklin Nyanzu, Pious Appiah, Jochebed Ode Boakye Ansah, Harry Campbell, Reiko Sato, Luis Jodar, et al.

    Background: Older adults in nursing and care homes (NCHs) are vulnerable to severe respiratory syncytial virus (RSV) infection, hospitalization, and death. This study aimed to gather data on RSV disease among older adults in NCHs and identify reported risk factors for RSV hospitalization and case fatality.Methods: The study protocol was registered in PROSPERO (CRD42022371908). We searched MEDLINE, EMBASE, and Global Health databases to identify articles published between 2000 and 2023. Observational and experimental studies conducted among older adults in NCHs requiring assistive care and reporting RSV illness were included and relevant data were extracted.Results: Of 18,690 studies screened, 32 were selected for full‐text review, and 20 were included. Overall, the number of NCH residents ranged from 42 to 1459 with a mean age between 67.6 and 85 years. Attack rates ranged from 6.7% to 47.6% and annual incidence ranged from 0.5% to 14%. Case fatality rates ranged from 7.7% to 23.1%. We found similar annual incidence rates of RSV‐positive acute respiratory infection (ARI) of 4582 (95% CI: 3259–6264) and 4785 (95% CI: 2258–10,141) per 100,000 reported in two studies. Annual incidence rate of RSV‐positive lower respiratory tract infection was 3040 (95% CI: 1986–4454) cases per 100,000 adults. Annual RSV‐ARI hospital admission rates were between 600 (95% CI: 190–10,000) and 1104 (95% CI: 350–1930) per 100,000 person‐years. Among all RSV disease cases, commonly reported chronic medical conditions included chronic obstructive pulmonary disease (COPD), heart failure, ischemic heart disease, coronary artery disease, hypertension, diabetes, kidney dysfunction, cerebrovascular accident, malignancies, dementia, and those with a Charlson comorbidity score > 6.5.Conclusion: Data on RSV infection among NCH residents are limited and largely heterogeneous but document a high risk of illness, frequent hospitalization, and high mortality. Preventive interventions, such as vaccination, should be considered for this high‐risk population. Nationally representative epidemiologic studies and NCH‐based viral pathogen surveillance could more precisely assess the burden on NCH residents.


  • Open Access

    Burden of Respiratory syncytial virus (RSV) infection among adults in nursing and care homes: a systematic review

    by Richard Osei-Yeboah, Stephen Amankwah, Elizabeth Begier, Miranda Adedze, Franklin Nyanzu, Pious Appiah, Jochebed Ode Boakye Ansah, Harry Campbell, Reiko Sato, Luis Jodar, et al.

    Background Older adults in nursing and care homes (NCHs) are vulnerable to severe respiratory syncytial virus (RSV) infection, hospitalisation, and death. This study aimed to gather data on RSV disease among older adults in NCHs and identify reported risk factors for RSV hospitalisation and case fatality. Methods The study protocol was registered in PROSPERO (CRD42022371908). We searched MEDLINE, EMBASE and Global Health databases to identify articles published between 2000 and 2023. Observational and experimental studies conducted among older adults in NCHs requiring assistive care and reporting RSV illness were included and relevant data were extracted. Results Of 18,690 studies screened, 32 were selected for full-text review and 20 were included. Overall, the number of NCH residents ranged from 42 to 1,459 with a mean age between 67.6 and 85 years. Attack rates ranged from 6.7 – 47.6% and annual incidence ranged from 0.5 – 14%. Case fatality rates ranged from 7.7 – 23.1%. We found similar annual incidence rates of RSV-positive acute respiratory infection (ARI) of 4,582 (95% CI: 3,259 – 6,264) and 4,785 (95% CI: 2,258 – 10,141) per 100,000 reported in two studies. Annual incidence rate of RSV-positive lower respiratory tract infection was 3,040 (95% CI: 1,986 – 4,454) cases per 100,000 adults. Annual RSV-ARI hospital admission rates were between 600 (95% CI: 190 -10,000) and 1,104 (95% CI: 350 – 1,930) per 100,000 person-years. Among all RSV disease cases, commonly reported chronic medical conditions included chronic obstructive pulmonary disease (COPD), heart failure, ischemic heart disease, coronary artery disease, hypertension, diabetes, kidney dysfunction, cerebrovascular accident, malignancies, dementia, and those with a Charlson comorbidity score > 6.5. Conclusion Data on RSV infection among NCH residents are limited and largely heterogeneous but document a high risk of illness, frequent hospitalisation, and high mortality. Preventive interventions, such as vaccination should be considered for this high-risk population. Nationally representative epidemiologic studies and NCH-based viral pathogen surveillance could more precisely assess the burden on NCH residents.


  • Open Access

    Isolation and Phenotypic Characterization of Virulent Bacteriophages Against Multidrug-Resistant Escherichia coli and Its Phage-Resistant Variant from Sewage Sources

    by Ashetu Fikadu, Stephen Amankwah, Bikila Alemu, Yared Alemu, Adisu Naga, Esayas Tekle, Tesfaye Kassa

    Purpose: The use of lytic bacteriophages for the control or elimination of pathogenic multidrug-resistant (MDR) bacteria is the promising alternative. However, the emergence of resistant bacterial variants after phage application may challenge its therapeutic benefit. In this study, we aimed to isolate candidate phages from sewage samples against two MDR Escherichia coli as well as their phage-resistant variant. Methods: MDR E. coli isolates (n = 10) obtained from Jimma Medical Center that had been properly identified and stored were used to isolate bacteriophages. Two lytic coliphages were isolated from hospital sewage samples following standard protocols. Upon single phage infection, phage-resistant variant quickly evolved serving as a new host for the isolation of a third lytic phage. This virulent phage’s lytic activity against both its host and the wild host was investigated. The host infectivity of the various cocktails was assessed, and each phage’s biological properties were studied. Results: Out of the first round of phage isolation process, two lytic phages were identified as VBO-E. coli 4307 and VBW-E. coli 4194. When exposed to VBO-E. coli 4307, the wild-type E. coli 4307 developed resistant variants. A third phage (VBA-E. coli 4307R) was isolated specific to this resistant variant (E. coli 4307R) under optimum condition. For VBO-E. coli 4307, VBW-E. coli 4194, and VBA-E. coli 4307R, the plaque assays generated under comparable conditions were 2.13 × 1010 PFU mL− 1, 9.17 × 1012 PFU mL− 1, and 3.3 × 1010 PFU mL− 1, respectively. These phages have nearly identical stability and lytic ability but differ greatly in their host ranges for VBA-E. coli 4307R. Conclusion: While the wild-type MDR pathogen could easily evolve resistance when exposed to a single phage infection by VBO-E. coli 4307, it is still possible to isolate a novel bacteriophage from environmental samples that is effective against the phage-resistant variants. This indicates that it is possible to manage the effects of phage resistance pathogens even if they are MDR.


  • Open Access

    Assessment of Phage-Mediated Inhibition and Removal of Multidrug-Resistant Pseudomonas aeruginosa Biofilm on Medical Implants

    by Stephen Amankwah, Mekonen Adisu, Kasahun Gorems, Kedir Abdella, Tesfaye Kassa

    Purpose: Despite the growing interest in bacteriophage (phage) usage for the prevention, control, and removal of bacterial biofilms, few scientific data exist on phage applications on medical implant surfaces, while none exists on multiple implants. In this study, we aimed to isolate, biophysically characterize and assess phages as potential antibiofilm agents to inhibit and remove multidrug-resistant (MDR) Pseudomonas aeruginosa biofilm on catheter and endotracheal tube surfaces. Methods: The well-identified stored clinical isolates (n = 7) of MDR P. aeruginosa were obtained from Jimma Medical Center. Specific phages were isolated and characterized based on standard protocols. The phages were tested for their antibiofilm effects in preventing colonization and removing preformed biofilms of MDR P. aeruginosa, following phage coating and treatment of catheter and endotracheal tube segments. Results: Two P. aeruginosa-specific phages (ΦJHS-PA1139 and ΦSMK-PA1139) were isolated from JMC compound sewage sources. The phages were biophysically characterized as being thermally stable up to 40°C and viable between pH 4.0 and 11.0. The two phages tested against clinical MDR strains of P. aeruginosa showed broad host ranges but not on other tested bacterial species. Both phages reduced MDR bacterial biofilms during the screening step. The phage-coated segments showed 1.2 log10 up to 3.2 log10 inhibition relative to non-coated segments following 6 h coating of segments prior to microbial load exposure. In both phages, 6 h treatment of the segments with 106 PFU/mL yielded 1.0 log10 up to 1.6 log10 reductions for ΦJHS and 1.6 log10 up to 2.4 log10 reductions for ΦSMK. Conclusion: Our results suggest that phages have great potential to serve the dual purpose as surface coating agents for preventing MDR bacterial colonization in medical implants and as biofilm removal agents in implant-associated infections.


  • Open Access

    Bacterial Biofilm Destruction: A Focused Review On The Recent Use of Phage-Based Strategies With Other Antibiofilm Agents

    by Stephen Amankwah, Kedir Abdusemed, Tesfaye Kassa

    Biofilms are bacterial communities that live in association with biotic or abiotic surfaces and enclosed in an extracellular polymeric substance. Their formation on both biotic and abiotic surfaces, including human tissue and medical device surfaces, pose a major threat causing chronic infections. In addition, current antibiotics and antiseptic agents have shown limited ability to completely remove biofilms. In this review, the authors provide an overview on the formation of bacterial biofilms and its characteristics, burden and evolution with phages. Moreover, the most recent possible use of phages and phage-derived enzymes to combat bacteria in biofilm structures is elucidated. From the emerging results, it can be concluded that despite successful use of phages and phage-derived products in destroying biofilms, they are mostly not adequate to eradicate all bacterial cells. Nevertheless, a combined therapy with the use of phages and/or phage-derived products with other antimicrobial agents including antibiotics, nanoparticles, and antimicrobial peptides may be effective approaches to remove biofilms from medical device surfaces and to treat their associated infections in humans.